Orchid Pharma Ltd Analyst Rating
based on 3 analysts
100.00%
Buy
0.00%
Hold
0.00%
Sell
Based on 3 analysts offering long term price targets for Orchid Pharma Ltd. An average target of ₹1545.33
Source: S&P Global Market Intelligence
Orchid Pharma Ltd Share analysis
Orchid Pharma Ltd price forecast by 3 analysts
Downside of
High
₹1710
Target
₹1545.33
Low
₹1285
Orchid Pharma Ltd target price ₹1545.33, a slight downside of -15.55% compared to current price of ₹1790.65. According to 3 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Orchid Pharma Ltd revenue growth forecast
Expected growth rate Q1, FY2026:82.29%
Forecast
Actual
Including amortisation and stock based compensations
Orchid Pharma Ltd EPS growth forecast
EPS estimate Q1, FY2026:119.76%
Forecast
Actual
Source: S&P Global Market Intelligence
Orchid Pharma Ltd Performance
Day's Low
Day's High
₹1,770.6Day's Price Range₹1,841.152 Week's Low
52 Week's High
₹675.252-Week Price Range₹1,841.1
| Returns % | |
| 1 Month Return | + 23.84 % |
| 3 Month Return | + 30.76 % |
| 1 Year Return | + 156.94 % |
| Market Stats | |
| Previous Close | ₹1,829.90 |
| Open | ₹1,840.25 |
| Volume | 61.25K |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹9,018.11Cr |
Orchid Pharma Ltd Key Statistics
| P/E Ratio | 75.77 |
| PEG Ratio | 45.92 |
| Market Cap | ₹9,018.11 Cr |
| P/B Ratio | 4.61 |
| EPS | 18.74 |
| Dividend Yield | 0 |
| Sector | Pharmaceuticals |
| ROE | 3.15 |
Orchid Pharma Ltd Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| BUY | ₹9,018.11 Cr | 2013.22% | 0.55 | ₹95 Cr | ₹819 Cr | |
| NA | ₹435.76 Cr | 272.24% | 0.54 | ₹28 Cr | ₹601 Cr | |
| NA | ₹15.41 Cr | 278.33% | 0.50 | NA | NA | |
| BUY | ₹23,100.09 Cr | 3.59% | 0.52 | NA | NA | |
| NA | ₹706.49 Cr | -0.07% | 0.57 | ₹9 Cr | ₹179 Cr |
Orchid Pharma Ltd Mutual Fund Holdings
About Orchid Pharma Ltd
Share Price: ₹1790.65 per share as on 20 Dec, 2024 04:01 PM
Market Capitalisation: ₹9,018.11Cr as of today
Revenue: ₹222.70Cr as on September 2024 (Q3 24)
Net Profit: ₹25.90Cr as on September 2024 (Q3 24)
Listing date: 12 May, 1995
Chairperson Name: Ram Gopal Agarwal
| Organisation | Orchid Pharma Ltd |
| Headquarters | |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
Key events for Orchid Pharma Ltd
Orchid Pharma Launches Antimicrobial Solutions Division - 06 Dec, 2024
Orchid Pharma's new Antimicrobial Solutions division aims to combat AMR and reduce hospital-acquired infections. Targeting the injectable segment, it plans to generate ₹200-250 crore in revenue within three years by expanding its sales team and penetrating hospitals.Orchid Pharma Reports Growth and AMR Collaboration - 25 Nov, 2024
Orchid Pharma announced a 12.05% increase in net sales for September 2024, alongside a collaboration with CAHO to address antimicrobial resistance, investing in diagnostics and committing sales towards AMR initiatives.Orchid Pharma Reports Strong Q3 Growth - 13 Nov, 2024
Orchid Pharma's standalone net sales for September 2024 reached Rs 222.70 crore, up 12.05% YoY. Net profit rose 26.6% to Rs 25.63 crore, with EBITDA increasing 17.79%. The EPS improved to Rs 5.05. The stock has delivered 46% returns over the last 6 months and 173.43% over the past year.Orchid Pharma Reports Strong Q2 Results, Shares Surge - 12 Nov, 2024
Orchid Pharma's Q2 FY25 results show a 26% increase in net profit and a 12% rise in revenue, leading to a 7% surge in shares.Orchid Pharma Reports Strong Q2 FY25 Results - 11 Nov, 2024
Orchid Pharma's Q2 FY25 results show a 12% revenue increase to ₹222.7 crore and a 26% rise in net profit to ₹25.6 crore. The company benefits from effective cost management and operational improvements, positioning itself for sustained growth in the pharmaceutical sector.
Insights on Orchid Pharma Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTFII Holding Up
Foreign Institutions have increased holdings from 1.42% to 1.94% in Sep 2024 quarter
- POSITIVE IMPACT
Best in 1 Year
In the last 1 year, ORCHPHARMA has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
- POSITIVE IMPACT
Best in 3 Years
In the last 3 years, ORCHPHARMA has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
- POSITIVE IMPACT
Price Rise
In the last 1 year, ORCHPHARMA stock has moved up by 150.2%
- POSITIVE IMPACT
Retail Holding Up
Retail Investor have increased holdings from 9.81% to 9.93% in Sep 2024 quarter
NO EFFECTPromoter Holding Unchanged
Promoters holdings remained unchanged at 69.84% of holdings in Sep 2024 quarter
NEGATIVE IMPACTRevenue Fall
Revenue is down for the last 2 quarters, 251.98 Cr → 230.22 Cr (in ₹), with an average decrease of 8.6% per quarter
- NEGATIVE IMPACT
Profit Down
Netprofit is down for the last 3 quarters, 32.96 Cr → 27.24 Cr (in ₹), with an average decrease of 9.1% per quarter
- NEGATIVE IMPACT
MF Holding Down
Mutual Funds have decreased holdings from 16.91% to 16.78% in Sep 2024 quarter
Orchid Pharma Ltd Financials
Index Inclusions
Orchid Pharma Ltd Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 69.84% | 0.00 | |
| Foreign Institutions | 1.94% | 36.07 | |
| Mutual Funds | 16.78% | ||
| Retail Investors | 9.93% | 1.23 | |
| Others | 1.51% |
Orchid Pharma Ltd Key Indicators
Orchid Pharma Ltd Valuation
Orchid Pharma Ltd in the last 5 years
Lowest (-871.56x)
April 8, 2022
Industry (56.23x)
December 19, 2024
Today (75.77x)
December 19, 2024
Highest (105.04x)
September 14, 2022
Orchid Pharma Ltd Earnings and Dividends
Orchid Pharma Ltd Earnings Results
Orchid Pharma Ltd’s net profit jumped 37.58% since last year same period to ₹27.24Cr in the Q2 2024-2025. On a quarterly growth basis, Orchid Pharma Ltd has generated -7.19% fall in its net profits since last 3-months.
Read More about Earnings Results
Orchid Pharma Ltd Technicals Summary
Bearish
Neutral
Bullish
Orchid Pharma Ltd is currently in a Bullish trading position according to technical analysis indicators.
FAQs on Orchid Pharma Ltd
- Get a PAN card.
- Open a Demat account.
- Open a Trading account.
- Link your Demat account to your Trading account.
- Fund your Trading account.
- Place an order to buy Orchid Pharma Ltd shares.
Orchid Pharma Ltd (ORCHPHARMA) share price today is ₹1790.65
Orchid Pharma Ltd is listed on NSE
Orchid Pharma Ltd is listed on BSE
- Today’s highest price of Orchid Pharma Ltd is ₹1841.1.
- Today’s lowest price of Orchid Pharma Ltd is ₹1770.6.
PE Ratio of Orchid Pharma Ltd is 75.77
PE ratio = Orchid Pharma Ltd Market price per share / Orchid Pharma Ltd Earnings per share
Today’s traded volume of Orchid Pharma Ltd(ORCHPHARMA) is 61.25K.
Today’s market capitalisation of Orchid Pharma Ltd(ORCHPHARMA) is ₹9018.11Cr.
| Orchid Pharma Ltd(ORCHPHARMA | Price |
|---|---|
52 Week High | ₹1841.1 |
52 Week Low | ₹675.2 |
Orchid Pharma Ltd(ORCHPHARMA) share price is ₹1790.65. It is down -2.74% from its 52 Week High price of ₹1841.1
Orchid Pharma Ltd(ORCHPHARMA) share price is ₹1790.65. It is up 165.20% from its 52 Week Low price of ₹675.2
| Orchid Pharma Ltd(ORCHPHARMA | Returns |
|---|---|
1 Day Returns | -39.25% |
1 Month Returns | 23.84% |
3 Month Returns | 30.76% |
1 Year Returns | 156.94% |